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Objective. Causes of small-bowel villous atrophy (VA) include coeliac disease (CD), its 
complications and other rare non-coeliac enteropathies. However, also forms of VA of unknown 
etiology may exist. We defined them idiopathic VA (IVA). To retrospectively classify the largest 
cohort of IVA patients and compare their natural history with CD. 
Methods. Notes of 76 IVA patients attending two tertiary centres between Jan-2000 and Mar-
2019 were retrospectively reviewed. CD, its complications and all the known causes of VA were 
excluded in all them. Persistence of VA during follow-up and lymphoproliferative features 
(gamma-TCR monoclonality and/or aberrant intraepithelial lymphocytes on duodenal biopsies 
and/or past history of extra-intestinal lymphoproliferative disorders) were used to retrospectively 
classify IVA, as follows. GROUP 1: IVA with spontaneous histological recovery (50 patients). GROUP 
2: persistent IVA without lymphoproliferative features (14 patients). GROUP 3: persistent IVA with 
lymphoproliferative features (12 patients). Survival was compared between IVA groups and 1114 
coeliac patients diagnosed between Jan-2000 and Dec-2017. HLA was compared between IVA 
patients and appropriate ethnicity-matched coeliac patients and healthy controls. 
Results. 5-year survival was 96% in IVA group 1, 100% in IVA group 2, 27% in IVA group 3 and 97% 
in CD. On a multivariate analysis hypoalbuminemia (< 3.5 g/dL, p=0.002) and age at diagnosis 
(p=0.04) predicted mortality in IVA. Group 2 showed association with HLA DQB1*0301 and 
DQB1*06. 
Conclusions. IVA consists of three groups of enteropathies with distinctive clinical phenotypes and 
prognosis. Mortality in IVA is higher than in CD and mainly due to lymphoprolipherative conditions 
necessitating more aggressive therapies. 




Coeliac disease (CD) is a chronic gluten-dependent enteropathy characterised by varying degrees 
of villous atrophy (VA) and a higher mortality than in the general population, mainly due to its 
complications [1-4]. Although small-bowel VA is due to CD and its complications in the vast 
majority of cases, these are not the only causes of VA and other non-coeliac enteropathies must 
be thoroughly investigated [5-11]. This is the case for autoimmune enteropathy (AE) [12,13], 
enteropathy associated with common variable immunodeficiency (CVID) [14,15], medication-
related enteropathies [16-21], infections [22-26], small-bowel bacterial overgrowth [27], some 
lymphoproliferative disorders primarily affecting the small bowel [28], Crohn’s disease [29], 
tropical sprue [30] and collagenous sprue [31]. Some contemporary reports suggest that overall 
mortality in non-coeliac enteropathies with VA is higher than in CD [5,8,10]. However, these 
papers do not compare mortality in each subtype of non-coeliac enteropathy to CD [8,10] and it is 
likely that long-term outcomes are slightly different within the heterogeneous group of non-
coeliac enteropathies [5-10, 12-16, 32] 
Finally, in some instances, no definitive etiology for small bowel VA can be precisely identified [5-
10, 33-36]. Even though patients with VA of unknown origin were described in small case series [5-
10, 33-36], their clinical phenotypes, HLA typing, histology, natural history and therapeutic 
management have never been investigated systematically so far. For the purpose of the present 
paper, we would like to refer to these rare and still obscure enteropathies as forms of idiopathic 
villous atrophy (IVA).  
By reporting the largest cohort of patients with small bowel IVA, the aims of this study are the 
following. Firstly, to retrospectively describe the clinical and histopathological phenotypes of 
patients with IVA (clinico-pathological study) and define their natural history and mortality in 
comparison to CD (follow-up and mortality study). Secondly, to study the HLA genetic profile of 
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patients with IVA and compare it with patients affected by CD and healthy controls (genetic 
study), as to understand whether, similarly to CD that develops in HLA DQ2/DQ8 individuals [1,2], 
a specific HLA genetic background could predispose to the development of these conditions.  
 
PATIENTS AND METHODS 
The study group included patients affected by small bowel IVA who attended two tertiary centres 
(Pavia, Italy and Sheffield, UK) between January 2000 and March 2019. 
 
Diagnostic criteria for IVA 
Patients with evidence of frank VA on correctly oriented biopsies (≥ Marsh 3a/Corazza-Villanacci 
grade B) taken from the second duodenal portion and in whom no specific cause for their VA was 
identified despite thorough investigations were enrolled. For patients referred to our centres, 
previous histology was carefully reviewed by expert histopathologists and only those with 
confirmed VA were included. In all these patients, CD and its complications as well as all the 
known causes of serology negative VA were excluded. More specifically, all the patients tested 
repeatedly negative to IgA endomysial antibodies (EmA), IgA tissue transglutaminase antibodies 
(TTG) and IgA gliadin antibodies. None had evidence of clinical and histological response to a 
gluten-free diet (GFD) and nobody had a family history of CD or a personal history of dermatitis 
herpetiformis. Enterocyte antibodies were negative and serum immunoglobulin levels normal, 
thus ruling out AE and CVID respectively. None of the patients were taking drugs known to be 
responsible for VA, namely ARBs, NSAIDS, methotrexate, mycophenolate [5,6,17-22]. Drug history 
was carefully reassessed particularly in those patients diagnosed before 2012, as to exclude a 
contributing role of olmesartan therapy [6]. Giardia specific stools antigens and other parasitic 
stool tests, tuberculosis quantiferon, HIV testing, small bowel aspirate/glucose H2-breath test, 
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Whipple’s PCR on duodenal biopsy/PAS staining on duodenal slides, H. Pylori were all negative. 
Traditional histology (ie. Hematoxylin and eosin staining, Masson’s trichrome stain) guided the 
exclusion of Crohn’s disease, collagenous sprue, eosinophilic enteritis, lymphoprolipherative 
disorders and malignancies primarily involving the small bowel, including those known to be 
complications of CD. None of the patients had predisposing factors for small intestinal bacterial 
overgrowth [5]. All patients in this study were asked to continue on a gluten containg diet while 
these investigations were carried out [5,7]. 
 
Criteria for the classification of IVA into clinical categories 
On the basis of our clinical experience and the previous literature describing some forms of IVA 
with spontaneous resolution [5,7,9,35,36] and others with persistence of VA [5-10,33,34], we set 
up criteria to retrospectively classify IVA patients into three groups (Figure 1). Patients in whom 
resolution of VA occurred spontaneously without any intervention (GFD, immunosuppressants) 
were classified into group 1. Conversely, patients displaying persistent VA unresponsive to at least 
12 months of a GFD or immunosuppressants were furtherly divided according to a combination of 
findings raising the suspicion of lymphoprolipherative features. These criteria included evidence of 
persistent gamma T-cell receptor (TCR) monoclonality on duodenal biopsies and/or presence of 
aberrant intraepithelial lymphocytes assessed by immunohistochemistry and/or flow cytometry, 
and/or past medical history of extraintestinal onco-haematological disorders. Patients in group 2 
did not meet any of the above mentioned criteria. Conversely, patients in group 3 displayed 






For the purpose of the clinico-pathological study baseline demographics, clinical and histological 
features of patients affected by IVA were retrospectively collected.  
For the follow-up and mortality study data on clinical and histological response to therapies, onset 
of complications (type and date of complication), date of last follow-up in clinic/death, cause of 
death (when available) were recordered for IVA patients until March 2019. Histological response 
was defined as an improvement in the degree of VA on follow-up duodenal biopsy. Clinical 
response was defined as resolution of symptoms.  
Survival was compared between IVA patients and 1114 coeliac patients (775 F, mean age at 
diagnosis 42±16 years) diagnosed in the two centres between January 2000 and December 2017 
and followed-up until March 2019 (cumulative follow-up: 8758.75 person/years). All the coeliac 
patients in the control group were diagnosed on the basis of VA and positive IgA EmA/TTG [1-2]. 
During follow-up, 25 of these coeliac patients (13F, mean age at diagnosis of CD 56±9 years) 
developed a complication (7 type 1 refractory CD, 4 type 2 refractory CD, 4 enteropathy associated 
T-cell lymphoma, 5 abdominal B-cell lymphomas, 2 small bowel carcinoma and 3 oesophageal 
cancer). A further survival analysis was made between this group of 25 patients with complicated 
CD and IVA patients. Diagnosis of the complications of CD was made as previously described [1-
4,37]. 
Finally, for the genetic study the HLA heterodimer frequencies of patients with IVA were 
compared to those of ethnicity-matched adult coeliac patients and healthy controls, in the same 
fashion we adopted in a previous study [38]. The control groups comprised 355 patients affected 
by uncomplicated CD (169 Italian- 122 females, mean age 31±14 years; 187 British – 130 females, 
mean age 44±17 years), 44 patients affected by complicated/refractory CD (27 Italian- 17 females, 
mean age 50±12 years; 17 British – 12 females, mean age 49±10) and 424 healthy controls (224 
Italian - 104 females, mean age 46±9 years; 200 British - 92 females, mean age 50.3±5.57). The 
7 
 
HLA typing of healthy controls was obtained from the registry of Stem Cells Donors of Pavia, as 
previously described [38] and from British Bone Marrow Registry. We note that for the group of 
British patients affected by refractory CD only the HLA DQB1 profile was available. We calculated 
the frequencies of HLA molecules encoding the heterodimers HLA-DQ2.5 (DQA1*05 DQB1*02), 
HLA-DQ2.2 (DQA1*02 DQB1*02), HLA-DQ7.3 (DQA1*03 DQB1*03:01), HLA-DQ7.5 (DQA1*05 
DQB1*03:01) and the DQB chain encoding for HLA-DQ5 (DQB1*05), HLA-DQ6 (DQB1*06), HLA-
DQ8 (DQB1*03:02) and HLA-DQ9 (DQB1*03:03). 
 
Histology 
Severity of VA was graded according to Marsh-Oberhuber classification [39] on hematoxilin and 
eosin stained slides from second duodenal portion. Traditional immunohistochemistry (IHC) for 
CD3 and CD8 lymphocyte markers was performed on formalin-fixed, paraffin-embedded duodenal 
specimens.  
Molecular analysis for gamma-TCR gene rearrangement was performed on DNA extracted from 
formalin-fixed paraffin embedded duodenal specimens by means of polymerase chain reaction, in 
accordance to standard Euroclonality/BIOMED-2 protocol.  
Aberrant intraepithelial lymphocytes, the hallmark of type 2 refractory coeliac disease, were 
identified as >50% of CD3+CD8- intraepithelial lymphocytes on traditional IHC or >20% CD3-CD8-




IgA/IgG EmA and IgA/IgG enterocyte antibodies were detected by means of indirect 
immunofluorescence on monkey oesophagus/jejunum slides (INOVA Diagnostics, San Diego, USA 
8 
 
was used for the Italian patients. The Binding Site, Birmingham, UK was used for the British 
patients). IgA/IgG TTG and deamidated gliadin antibodies were tested by using ELISA kits (EliA 
Celikey IgA and Celikey IgG, EliA Gliadin DP IgA and EliA Gliadin DP IgG; Phadi AB, Uppsala, Sweden 
were used for the Italian patients. Aesku Diagnostics, Wendelsheims, Germany was used for the 




Italian patients and controls were typed for HLA class II genomic polymorphisms at the high-
resolution level by means of sequences specific primers- polymerase chain reaction (PCR-SSP) 
and/or polymerase chain reaction utilising sequence-specific primary oligonucleotides (PCR-SSO) 
[40,41]. DNA was extracted from peripheral blood samples using the Wizard genomic DNA 
Purification kit (Maxwell 16®, Promega Instrument; Madison, WI, USA) according to the 
manufacturer’s protocol. The polymorphism of the HLA-DQA1 and DQB1 genes was analyzed using 
commercial kits (Olerup SSP AB®, Stockholm, Sweden), and One Lambda Inc.; Canoga Park, CA, 
USA). The amplified products were visualized on 2% agarose gel, stained with 0.5 mg/mL of 
ethidium bromide, using the E-Gel precast Agarose Electrophoresis System (Invitrogen Life 
Technologies®, PA4 9RF Paisley, UK).  
For British patients the HLA typing was obtained by means of a sequence-specific oligonucleotide 
polymerase chain reaction technique (LIFECODES HLA SSO typing – RAPID, IMMUCOR ® Georgia, 
USA). Genomic DNA was extracted from samples of peripheral blood using a DNA purification kit in 
combination with an automated DNA extraction platform (MagNA Pure Compact DNA Nucleic Acid 
Isolation kit and a MagNA Pure Compact instrument Roche Basel, Switzerland). For BBMR the 
automated DNA extraction platform used was Qiasymphony (QIAGEN®, Venlo, Netherlands). 
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Results were analysed using a Luminex ® 100 analyser (Luminex® Corporation Texas, USA) and 
MATCH IT! analysis software (IMMUCOR ® Georgia, USA). 
 
Statistical analysis 
Categorical variables were described as count and percentages; quantitative variables as mean 
and standard deviation if normally distributed (Shapiro-Wilks test), otherwise as median and 
percentiles. Clinical, laboratory and histopathological features were compared between IVA 
groups using one-way analysis of variance for normally distributed quantitative variables followed 
by Scheffè corrected 2x2 post-hoc comparisons. Categorical data were compared between the IVA 
and control groups by means of χ2 test and Fisher’s exact test followed by Bonferoni corrected 2x2 
post-hoc comparisons. 
HLA heterodimers frequencies were compared between the IVA and control groups by means of 
χ2 test and Fisher’s exact test. For the genetic study, a correspondence analysis, which represents 
an explorative multivariate statistical technique, was used to provide a graphical interpretation in 
a bidimensional graph of the relationship between the clinical groups (three IVA groups vs. coeliac 
patients and healthy controls) and the genetic variants [38]. 
Overall survival was described through a Kaplan-Meier curve. Univariate and multivariate 
(including factors significantly associated with survival at univariate analysis) Cox models were 
fitted to study long-term mortality. Results are expressed as hazard ratio (HR) and reported with 
95% CI. 
P-value <.05 was considered statistically significant. All tests were two-sided. The data analysis 
was performed with the STATA statistical package (release 15.1, 2017, Stata Corporation, College 





All the patients gave an informed consent at time of duodenal biopsy, both for clinical and 
research purposes. After verifying the good quality of the data, they were all irreversibly 
anonymised. The study was approved by the Ethics committee of the Fondazione IRCCS Policlinico 
San Matteo, Pavia, Italy according to the 1975 declaration of Helsinki (6th revision, 2008). 
Similarly, the study protocol was approved by the Yorkshire and Humber Research Ethics 
committee and registered with the local research and development department of Sheffield 
Teaching Hospital NHS Foundation Trust (REC reference 14/YH/1216). 
 
RESULTS 
Seventy-six patients affected by IVA were collected over a period of 17 years. Their baseline 
demographics, clinical characteristics, laboratory results and radiological findings are shown in 
Table 1. The most common presenting symptoms were weight loss, diarrhoea and dyspepsia. 
Weight loss was more frequent among patients with persistent VA, being significantly associated 
to group 3 (p=.01). Prevalence of dyspepsia was higher in group 1 (p=.003). Anaemia and 
hypoalbuminemia (< 3.5 g/dL) were more common in group 3 (p<.001). Family history of 
autoimmune disorders was more common in group 2 (p=.01). 
 
Follow-up and mortality 
Complete spontaneous histological recovery occurred in 47/50 patients in group 1 (Table 2) after a 
median of 10 months [IQR 5-14 months], whereas the remaining three patients declined follow-up 
biopsy given their persistent well-being. Four patients spontaneously started on a GFD for a few 
months after diagnosis of IVA, but then resumed and all were on a normal diet at time of 
histological follow-up. In group 2 (table 3), histological and clinical response to 
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immunosuppressant/biologics occurred in 5/14 patients. More precisely, two responded to 
azathioprine, one to open-capsule budesonide treatment and two to biologics (patients 1, 6, 12-
14). In other two patients (n° 2 on azathioprine and n° 8 on budesonide), despite clinical response 
had occurred, histological recovery was slow. Conversely, in group 3 (table 4), 10 out of 12 
patients had persistence of VA on follow-up biopsy and one refused follow-up gastroscopy. 
Complications were found in one patient in group 2 (patients 14, Table 3) and nine patients in 
group 3 (p<0.001). Median time from diagnosis of VA to development of complications in group 3 
IVA was 13 months, IQR 3.5-26.5. 
Eleven out of 76 patients (14.5%) died (4 in group 1 IVA for causes unrelated to the enteropathy, 
after a median time since diagnosis of 4.5 years; 7 patients in group 3 IVA, mainly because of a 
lymphoprolipherative malignancy after a median of 15 months, IQR 9.5-40.5). Patients in group 2 
were all alive after a median follow-up of 64 months, IQR 52-114. In the coeliac cohort 66/1114 
patients (5.92%) died. Causes of death in this group included complicated CD in 13/66 (19.6%), 
cardiovascular causes in 9/66 (13.6%), other cancers in 8/66 (12.1%, including extra-intestinal 
epithelial malignancies), pneumonia in 8/66 (12.1%). In 13 patients the cause of death was 
unknown and in the remaining 15 the causes were heterogeneous. We specify that the 8 coeliac 
patients deceased because of cancers were not affected by a complicated or refractory form of 
CD. 
Figure 2 shows Kaplan-Meier estimated survival in IVA and coeliac patients. Mortality in IVA was 
higher than in CD (Fig 2A, p<.001), but with great differences within the three IVA groups (Fig 2B). 
Overall 5-year survival was 96% in IVA group 1, 100% in IVA group 2, 27% in IVA group 3 and 97% 
in the coeliac cohort. There was no difference in long-term survival between IVA group 1 and CD 
(p=.22). Patients in group 3 IVA showed the poorest prognosis, even when compared to the 25 
coeliac patients that developed a complicated form of CD (Fig 2C, p<.001). 
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On univariate analysis age at diagnosis (HR 1.05, 95%CI 10.1-1.09, p=.009), anaemia (HR 7.8, 95%CI 
2.18-27.80, p=.002), hypoalbuminemia (HR 16.2, 95%CI 4.68-56.58, p<.001) and HLA DQ2.2 (HR 
5.7, 95% CI 1.74-18.9, p=.004) were statistically significant predictors of mortality in IVA patients, 
whereas dyspepsia was a protective factor (HR 0.12, 95%CI 0.015-0.96, p=.046). Gender (HR 0.79, 
95% CI 0.24-2.62, p=.707), diarrhoea (HR 1.11, 95% CI 0.32-3.77, p=.877), weight loss (HR 1.78, 
95% CI 0.47-6.74, p=.393) and HLA DQ2.5 (HR 1.49, 95% CI 0.39-5.69, p=.560) were not 
significantly associated to increased mortality. On multivariate analysis only age at diagnosis (HR 
1.04, 95%CI 1.00-1.07, p=.03) and hypoalbuminaemia (HR 10.7, 95%CI 2.32-50.00, p=.002) 
significantly predicted mortality. 
 
Histopathological and molecular features 
As shown in Table 1 partial VA was the histological hallmark of group 1 (p<.001), while no 
significant differences were found for intraepithelial lymphocytosis and crypt hyperplasia. 
Histopathological findings for group 1 and group 2 are specified in Table 2 and Table 3. Briefly, in 
group 1 histology was undistinguishable from untreated CD in the vast majority of patients and 
only in 6/50 histological features were in keeping with peptic duodenitis [24] (Table 2). In group 2 
a coeliac-like pattern, characterized by crypt hyperplasia and intraepithelial lymphocytosis with 
normal CD3+ CD8+ phenotype, was evident in 11 patients (no 1-11, table 3). Only in one patient (no 
4 in Table 3) histology revealed a subepithelial band of collagen, though criteria for collagenous 
sprue were not met [31]. A peptic duodenitis-like pattern characterised by expansion of the lamina 
propria by a mixed but predominantly mononuclear inflammatory infiltrate and neutrophilic 
cryptitis was found in 3 patients (no 12-14). Interestingly, two of them had a diagnosis of ulcerative 
colitis. All patients in group 2 showed regular phenotype of intraepithelia lymphocytes assessed by 
FC or IHC and/or polyclonal gamma-TCR both at time of diagnosis and during follow-up. 
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Table 4 summarises the heterogeneous histological features of group 3. An aberrant histology 
and/or persistent monoclonality for gamma-TCR were found in patients 1-6. Patient 7 refused 
follow-up, so we were not able to assess persistence or resolution of gamma-TCR monoclonality. 
Histology undistinguishable from conventional CD was found in patients 6 and 8-12. In patients 9 
and 10 a band of subepithelial collagen was found. They both had a history of chemotherapy for 
extraintestinal lymphoprolipherative disorders. However, histological findings were neither 




Comparison of the HLA heterodimers frequencies between IVA groups, healthy controls and 
coeliac patients is shown in Table 5. Of note, in group 2 HLA-DQ7.3 was carried by 33% of patients 
and HLA-DQ6 by nearly 60% (p<.001). In group 3, HLA-DQ5 molecules were carried by 41.65% of 
patients and HLA-DQ2 by half of them. Group 1 IVA was genetically heterogeneous, with HLA-
DQ2.5 (35%) and HLA-DQ6 (45%), being the most frequent molecules. As expected, HLA-DQ2 
molecules were more commonly expressed by coeliac patients. HLA-DQ8 was poorly expressed by 
group 3 IVA and patients with complicated CD. 
A graphical visualization of the genetic HLA diversity between the three IVA groups, coeliac 
patients and healthy controls is shown by the correspondence analysis on heterodimers in Figure 
3. The analysis confirms that group 2 IVA is HLA genetically different from coeliac patients, being 
associated with HLA-DQ7.3 and HLA-DQ6 molecules. On the contrary, group 1 and 3 IVA, despite 





In this study we have described the largest cohort of patients with small bowel IVA and we have 
provided a clinical-based classification of these enteropathies into three groups with distinctive 
clinical features, HLA and natural history. We have given the most extensive description about 
long-term outcomes in IVA, showing for the first time that mortality in IVA is overall higher than in 
CD, though remarkably different between IVA subgroups. More specifically, IVA patients with 
lymphoprolipherative features (group 3) are burdened by the poorest prognosis and are mainly 
responsible for the higher mortality found in IVA than in CD. Age and hypoalbuminaemia at time 
of diagnosis of VA are important predictors of mortality in IVA and may be helpful to stratify 
patients warranting a more aggressive treatment and close follow-up. Our results on IVA add to 
some previous studies suggesting that overall mortality in non-coeliac enteropathies with VA is 
higher than in in CD [5,8,10,32]. 
The clinical features of patients with self-limited IVA (group 1) were already described in the past 
[5,7,9,35,36]. The novel finding of our study is that mortality in these patients is not higher than in 
CD and it is mainly due to causes unrelated to the enteropathy. This is in line with a less severe 
and transient enteropathy, maybe triggered by viral infectious agents, as previously hypothesised 
[5,7,9,35,36]. 
Another strength of our study is the identification of diagnostic criteria for a new form of chronic 
non-coeliac enteropathy characterised by persistent VA, absence of any lymphoprolipherative 
stigmata, specific HLA typing and long-term survival (ie. IVA group 2). Although similar patients 
were described in the past [5-10,33,34,42], we have now provided a more detailed description of 
their clinical and molecular phenotype. The first mandatory diagnostic criteria are the presence of 
a regular phenotype of intraepithelial lymphocytes assessed by IHC and/or FC and the absence of 
monoclonality for gamma-TCR both at time of diagnosis and during follow-up, thus excluding type 
2 refractory CD [37]. Secondly, the HLA genetic background is dominated by HLA DQ7.3 and DQ6 
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molecules that are not listed among those conferring risk for developing CD [43]. Although it might 
be said that patients with similar features are affected by seronegative CD or refractory CD, we 
believe that HLA genetic background, the histological and molecular phenotypes, the absence of 
any sensitivity to gluten and the long-term survival are key to define a distinct clinical entity. 
Despite the quite high response rate to immunosuppressants and the high prevalence of family 
history for autoimmune disorders may support the hypothesis of an immune-driven chronic 
enteropathy, we think this is not sufficient to confirm a diagnosis of AE, given the negative results 
for enterocyte antibodies. While forms of seronegative AE do exist and are well defined in 
children, their existence in adults needs to be furtherly elucidated [5,12,13,42]. 
Interestingly, two main histological patterns were identifiable in group 2: a coeliac-like pattern in 
78% of the patients and a peptic duodenitis-like pattern in the remaining 22%. All the patients 
with peptic duodenitis-like histology responded histologically to immunusuppressant and/or 
biologics. Two were concomitantly diagnosed with ulcerative colitis. Similar small bowel histology 
was previously described in patients with ulcerative colitis [44]. On the contrary, fewer patients 
with a coeliac-like pattern had histological response to traditional immunosuppressants. 
Group 3 is burdened by a very high mortality that is mainly responsible for the poorer outcome we 
found in IVA than in CD. Identification of these patients was made on the basis of persistent 
monoclonality for gamma-TCR and a previous history of extra-intestinal lymphoproliferative 
disorders. However, this group is the most heterogeneous in terms of histological features, with 
some points that are worth discussing. 
First, the specificity of gamma-TCR monoclonality analysis has recently been questioned, with 
transient monoclonal gamma-TCR described also in coeliac patients with poor compliance to a 
GFD, [45, 46] and even in patients with duodenal lymphocytosis associated to H. Pylori [47]. 
However, in our patients in group 3 monoclonality was persistent on follow-up biopsies in five out 
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of six patients (one refused follow-up). Most importantly, three of them developed 
lymphoproliferative complications and 50% of them died (patients 1-6, table 4). This would enable 
us to identify within group 3 a subgroup of patient with IVA, persistent monoclonality for gamma-
TCR and high risk of lymphoproliferation. 
The second criterion we adopted is previous history of extra-intestinal lymphoproliferative 
disorders. Four patients had a history of lymphoproliferative disorders pre-dating the diagnosis of 
VA (patients 7-10, table 4). Two of them received chemotherapy some years before and one was 
on treatment with idelalisib at time of diagnosis of IVA. Hence, a possible role of these 
medications in promoting a certain damage to the small bowel, although very remote, cannot be 
entirely excluded. Interestingly, forms of enterocolitis possibly related to idelalisib have been 
described [48]. 
Last but not least, two patients in this group (no 11 and 12 in Table 4) were very difficult to be 
classified. From one side they did not show any clear molecular lymphoproliferative features at 
diagnosis, so they would have matched with group 2. However, the clinical suspicion had always 
been that of a lymphoma in both them. During follow-up one of them deteriorated and died of 
angioimmunoblastic T-cell lymphoma and the other died of oesophageal cancer within less than 
four years from diagnosis.  
Finally, although CD and its complications were thoroughly excluded at time of diagnosis of VA, we 
noticed that some patients in group 3 died because of conditions that could be considered 
complications of CD. HLA DQ2 molecules were found in half of the patients in group 3, so we 
wonder whether they were seronegative coeliac patients that escaped the diagnosis before and 
then complicated afterwards. 
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Partial villous atrophy, absence of suspicious features for lymphoproliferation, and normal 
laboratory tests at diagnosis identify patients with a self-limited form of VA (group 1). These 
patients should not be prescribed a GFD and the most appropriate management may be a “watch 
and wait” strategy for at least six months, before assessing for histological recovery. This would 
avoid misdiagnoses of seronegative CD, particularly in those carrying HLA DQ2 or DQ8 molecules.  
On the contrary, age at diagnosis and hypoalbuminaemia are important predictors to identify 
since the time of diagnosis patients with persistent IVA that should warrant aggressive treatments 
and close follow-up. In patients with persistent VA of unknown etiology we suggest to always 
characterise the phenotype of intraepithelial lymphocytes by means of IHC and/or FC and to test 
for gamma-TCR clonality, since in patients with negative results for these tests prognosis is 
excellent (ie. Group 2 IVA).  
In conclusion, we think this study can represent a first step in the description of rare enteropathies 
with VA of unknown origin. Proposals for future research may include the investigation of the 
molecular pathways involved in IVA, a further discrimination of enteropathies displaying 
lymphoproliferative features and the evaluation of the therapeutic potential of regimens 
alternative to traditional immunosuppressants. Depending on the nature of the enteropathy, 
these could include autologous and allogeneic haemopoietic cellular therapies [49-51], both as 
rescue therapy for patients refractory to conventional immunosuppressants or as first line therapy 
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LEGENDS FOR TABLES  
Table 1. Baseline characteristics of patients with idiopathic villous atrophy 
IVA: idiopathic villous atrophy; PVA: partial villous atrophy; SVA: subtotal villous atrophy; TVA: 
total villous atrophy; IELs: intraepithelial lymphocytes; CH: cripth hyperplasia; SD: standard 
deviation; VCE: video capsule endoscopy; CT: computed tomography 
 
Table 2. Histological features and outcomes in patients belonging to group 1 
CPD: chronic peptic duodenitis; f-up: follow-up 
 
 
Table 3. Histological features and outcomes in patients belonging to group 2 
LPD: lymphoprolipherative disorders; CT: computed tomography; NA: not assessed; SB: small-
bowel; UC: ulcerative colitis; GFD: gluten-free diet; UJI: ulcerative jejunitis; 6-MPU: 6 
mercaptopurine; AZA: azathioprine; mo: months since diagnosis 
 
 
Table 4. Histological features and outcomes in patients belonging to group 3 
LPD: lymphoprolipherative disorders; CT: computed tomography; NA: not assessed; SB: small-
bowel; TCL: T-cell lymphoma; BCL: B-cell lymphoma; NHL: non Hodgkin lymphoma; GFD: gluten-
free diet; TI: terminal ileum; UJI: ulcerative jejunitis; diagn: diagnosis; f-up: follow-up; LN: lymph 
nodes; AZA: azathioprine; MSC: mesenchymal stem cells; resp.: response 
 
 
Table 5. HLA heterodimers distribution in patients with idiopathic villous atrophy, coeliac 
disease and healthy controls. 
HC: healthy controls; IVA: idiopathic villous atrophy; CCD: complicated coeliac disease; UCD: 






LEGENDS FOR FIGURES 
 
Figure 1. Criteria to classify idiopathic villous atrophy into clinical categories. 
 




Figure 2. Kaplan Meier estimated survival curves for idiopathic villous atrophy groups 
compared to coeliac disease.  




Figure 3. Genetic heterogeneity of idiopathic villous atrophy patients compared to 
coeliac patients and healthy controls. The correspondence analysis shows that the nearer 
the dots, the stronger the association. Black squares indicate the group of patients. Blue 
dots indicate HLA heterodimers (HLA-DQ2.5 encoded by DQA1*05 DQB1*02, HLA-DQ2.2 
encoded by DQA1*02 DQB1*02, HLA-DQ7.3 encoded by DQA1*03 DQB1*03:01, HLA-
DQ7.5 encoded by DQA1*05 DQB1*03:01) and green dots indicate DQB chains. CD: coeliac 
disease; IVA: idiopathic villous atrophy; HC: healthy controls 
Figure  1. Click here to access/download;Figure;FIGURE 1.jpg
Figure 2. Click here to access/download;Figure;FIGURE 2.jpg




























Mean age±SD 48.5±17.7 49.2±18.7 43.3±13.8 51.9±13.8 0.431 - - - 
Females, no 38 26 7 5 0.813 - - - 
Caucasian ethnicity 70 46 13 11 0.933 - - - 
CLINICAL FEATURES, LABORATORY AND RADIOLOGICAL FINDINGS AT DIAGNOSIS 
Diarrhoea 46 27 9 10 0.166 - - - 
Weight loss 47 25 11 11 0.01 0.05 0.009 0.356 
Abdominal pain 22 13 4 5 0.561 - - - 
Reflux 14 11 3 0 0.200 - - - 
Dyspepsia 29 26 2 1 0.003 0.01 0.006 0.636 
Vomiting 20 15 2 3 0.495 - - - 
Anaemia 21 6 5 10 <0.001 0.03 <0.001 0.01 
Hypoalbuminemia 
(<3.5g/dl) 
12 0 4 8 <0.001 <0.001 <0.001 0.05 
Low folate 10 1 4 5 <0.001 0.001 <0.001 0.484 
Low B12 19 8 5 6 0.03 0.105 0.01 0.462 
Low ferritin 17 6 9 2 <0.001 <0.001 0.665 0.014 
Pathological VCE findings 25 5 13 7 <0.001 <0.001 <0.001 0.45 
Pathological CT findings 7 0 1 6 0.001 0.237 0.001 0.016 
PAST MEDICAL HISTORY 
Autoimmunity 14 8 2 4 0.345 - - - 
Family history of  
autoimmune diseases 
2 0 2 0 0.01 0.007  0.173 
Travel endemics 8 6 2 0 0.420 - - - 
Gastroenteritis 12 11 0 1 0.101 - - - 
DUODENAL HISTOLOGY AT DIAGNOSIS 
Histology_Marsh 3a 53 49 0 4 <0.001 - - - 
Histology_Marsh 3b +3c 23 1 14 8 <0.001 <0.001 <0.001 0.019 
Histology_IELs 69 44 13 12 0.416 - - - 
















1 18/M Marsh 3a CPD f-up refused Alive (27) 
2 48/M Marsh 3a CPD Marsh 0 (105) Alive (107) 
3 40/M Marsh 3a Coeliac-like 
Marsh 3c (7) 
Marsh 1 (94) 
Alive (98) 
4 28/F Marsh 3a Coeliac-like Marsh 0 (4) Alive (24) 
5 18/M Marsh 3a Coeliac-like Marsh 1,CPD (48) Alive (73) 
6 58/M Marsh 3a Coeliac-like Marsh 1 (11) Alive (77) 
7 49/F Marsh 3a Coeliac-like Marsh 1 (11) Alive (81) 
8 40/M Marsh 3a Coeliac-like Marsh 1 (3) Alive (147) 
9 30/M Marsh 3a Coeliac-like Marsh 1 (4) Alive (156) 
10 73/F Marsh 3a Coeliac-like Marsh 1 (54) Alive (68) 
11 58/F Marsh 3a Coeliac-like Marsh 1 (6) Alive (146) 
12 80/F Marsh 3a Coeliac-like Marsh 1 (12) Dead (105) 
13 85/F Marsh 3a Coeliac-like Marsh 1 (5) Dead (14) 
14 28/M Marsh 3a Coeliac-like Marsh 1 (7) Alive (67) 
15 73/F Marsh 3a Coeliac-like Marsh 1 (2) Alive (60) 
16 45/M Marsh 3a CPD Marsh 1 (14) Alive (60) 
17 67/M Marsh 3a Coeliac-like Marsh 0 (28) Alive (80) 
18 71/F Marsh 3a Coeliac-like Marsh 1 (10) Dead (38) 
19 59/M Marsh 3a Coeliac-like 
Marsh 3a (18), then 
lost f-up 
Alive (105) 
20 27/F Marsh 3a Coeliac-like 
Marsh 3b (2) 
Marsh 1, (15) 
Alive (111) 
21 78/F Marsh 3a Coeliac-like Marsh 1,CPD (6) Dead (69) 
22 68/M Marsh 3a Coeliac-like Marsh 0 (5) Alive (129) 
23 30/F Marsh 3a Coeliac-like Marsh 1 (15) Alive (91) 
24 31/F Marsh 3a Coeliac-like Marsh 0 (5) Alive (99) 
25 65/F Marsh 3a Coeliac-like Marsh 1 (14) Alive (88) 
26 42/F Marsh 3a Coeliac-like Marsh 0 (20) Alive (94) 
27 66/M Marsh 3a Coeliac-like 
Marsh 3a (5) 
Marsh 1 (28) 
Alive (115) 
28 59/M Marsh 3a Coeliac-like 
Marsh 3a (4) 
Marsh 1 (16) 
Alive (114) 
29 51/M Marsh 3a CPD Marsh 1 (6) Alive (68) 
30 48/M Marsh 3a Coeliac-like Marsh 1 (3) Alive (123) 
31 59/F Marsh 3a Coeliac-like Marsh 0 (14) Alive (165) 
32 46/M Marsh 3a Coeliac-like Marsh 1 (1) Alive (145) 
33 56/M Marsh 3a Coeliac-like Marsh 0 (5) Alive (81) 
34 37/F Marsh 3b Coeliac-like Marsh 0 (4) Alive (82) 
35 62/M Marsh 3a Coeliac-like Marsh 0 (9) Alive (118) 
36 23/F Marsh 3a Coeliac-like Marsh  0 (8) Alive (22) 
37 64/F Marsh 3a Coeliac-like Marsh 1 (6) Alive (67) 
38 62/F Marsh 3a Coeliac-like 
Marsh 3a (5) 
Marsh 1 (83) 
Alive (97) 
39 69/F Marsh 3a Coeliac-like Marsh 1 (5) Alive (23) 
40 66/F Marsh 3a Coeliac-like Marsh 1 (3) Alive (67) 
41 18/F Marsh 3a Coeliac-like Marsh 0 (15) Alive (179) 
42 43/`M Marsh 3a Coeliac-like F-up refused Alive (63) 
43 53/M Marsh 3a CPD Marsh 0 (11) Alive (22) 
44 21/M Marsh 3a Coeliac-like Marsh 0 (7) Alive (19) 
45 48/F Marsh 3a Coeliac-like Marsh 1 (23) Alive (33) 
46 29/M Marsh 3a CPD Marsh 1 (4) Alive (57) 
47 64/M Marsh 3a Coeliac-like Marsh 1 (14) Alive (26) 
48 61/F Marsh 3a Coeliac-like Marsh 0 (9) Alive (61) 
49 31/F Marsh 3a Coeliac-like Marsh 0 (13) Alive (68) 


















































































































64/F DQ2.5/DQ6 - normal Marsh 3c 
Poly-
clonal 






























































57/M DQ2.5/DQ2.5 - NA Marsh 3b 
Poly-
clonal 









































































































57/M DQ2.5/DQ2.5 - UJI Marsh 3c Mono-
clonal 
Aberrant CD3+CD8- CD2- 









37/F DQ7.5/DQ7.5 - normal Marsh 3c Mono-
clonal 
Aberrant CD3+CD8- CD2- 





No Marsh 3c Extensive 
SB mosaic 








No increased IELS, 
increased numbers of 
lymphocytes and plasma 
















partial refused Extensive 
SB mosaic 













 Chronic CD3+ CD8+ 




































Full thickness biopsy: 
band of collagen 













GFD+budesonide No Marsh 3a Extensive 
SB mosaic 














87/M DQ5/DQ6 - NA Marsh 3c NA Coeliac-like GFD+ 
Prednisolone+AZA 















CCD UCD p-value 

































































DQ7 ALL 150/424 
(35.38%) 
12/40 
(30.00%) 
6/12 
(50.00%) 
3/12 
(25.00%) 
7/44 
(15.91%) 
63/355 
(17.75%) 
<0.001 
DQ7.3 1/424 
(0.24%) 
5/40 
(12.50%) 
4/12 
(33.33%) 
2/12 
(16.67%) 
0/44 
(0%) 
0/355 
(0%) 
<0.001 
DQ7.5 149/424 
(35.14%) 
8/40 
(20.0%) 
3/12 
(25.00%) 
2/12 
(16.67%) 
7/44 
(15.91%) 
63/355 
(17.74%) 
<0.001 
DQ8 75/424 
(17.69%) 
7/40 
(17.50%) 
1/12 
(8.33%) 
0/12 
(0%) 
1/44 
(2.27%) 
44/355 
(12.39%) 
0.025 
DQ9 34/424 
(8.02%) 
3/40 
(7.50%) 
2/12 
(16.67%) 
1/12 
(8.33%) 
0/44 
(0%) 
5/355 
(1.40%) 
<0.001 
 
Table 5
